Literature DB >> 22158359

What's fueling the biotech engine--2010 to 2011.

Saurabh Aggarwal1.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22158359     DOI： 10.1038/nbt.2060

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  16 in total

1.  Targeted cancer therapies.

Authors:  Saurabh Aggarwal
Journal:  Nat Rev Drug Discov       Date:  2010-06       Impact factor: 84.694

2.  What's fueling the biotech engine-2009-2010.

Authors:  Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2010-11       Impact factor: 54.908

3.  What's fueling the biotech engine?

Authors:  Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2007-10       Impact factor: 54.908

4.  Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study.

Authors:  K Noyes; A Bajorska; A Chappel; S R Schwid; L R Mehta; B Weinstock-Guttman; R G Holloway; A W Dick
Journal:  Neurology       Date:  2011-07-20       Impact factor: 9.910

5.  Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.

Authors:  Jipan Xie; Madhav Namjoshi; Eric Q Wu; Kejal Parikh; Melissa Diener; Andrew P Yu; Amy Guo; Kenneth W Culver
Journal:  J Manag Care Pharm       Date:  2011-10

6.  Boceprevir for untreated chronic HCV genotype 1 infection.

Authors:  Fred Poordad; Jonathan McCone; Bruce R Bacon; Savino Bruno; Michael P Manns; Mark S Sulkowski; Ira M Jacobson; K Rajender Reddy; Zachary D Goodman; Navdeep Boparai; Mark J DiNubile; Vilma Sniukiene; Clifford A Brass; Janice K Albrecht; Jean-Pierre Bronowicki
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

7.  Response-guided telaprevir combination treatment for hepatitis C virus infection.

Authors:  Kenneth E Sherman; Steven L Flamm; Nezam H Afdhal; David R Nelson; Mark S Sulkowski; Gregory T Everson; Michael W Fried; Michael Adler; Hendrik W Reesink; Marie Martin; Abdul J Sankoh; Nathalie Adda; Robert S Kauffman; Shelley George; Christopher I Wright; Fred Poordad
Journal:  N Engl J Med       Date:  2011-09-15       Impact factor: 91.245

8.  Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

Authors:  Bernard Zinman; Greg Fulcher; Paturi V Rao; Nihal Thomas; Lars A Endahl; Thue Johansen; Rebecka Lindh; Andrew Lewin; Julio Rosenstock; Michel Pinget; Chantal Mathieu
Journal:  Lancet       Date:  2011-03-12       Impact factor: 79.321

9.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

Review 10.  Systemic lupus erythematosus in the elderly.

Authors:  J Rovenský; A Tuchynová
Journal:  Autoimmun Rev       Date:  2007-12-03       Impact factor: 9.754
View more
  21 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 2.  ADME of biologics-what have we learned from small molecules?

Authors:  Thomayant Prueksaritanont; Cuyue Tang
Journal:  AAPS J       Date:  2012-04-07       Impact factor: 4.009

Review 3.  Protein particulate detection issues in biotherapeutics development--current status.

Authors:  Tapan K Das
Journal:  AAPS PharmSciTech       Date:  2012-05-08       Impact factor: 3.246

4.  What's fueling the biotech engine-2011 to 2012.

Authors:  Saurabh Rob Aggarwal
Journal:  Nat Biotechnol       Date:  2012-12       Impact factor: 54.908

5.  A survey of applications of biological products for drug interference of immunogenicity assays.

Authors:  Yow-Ming C Wang; Lanyan Fang; Lin Zhou; Jie Wang; Hae-Young Ahn
Journal:  Pharm Res       Date:  2012-08-18       Impact factor: 4.200

6.  Industry pursues co-stimulatory receptor immunomodulators to treat cancer.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908

7.  What's fueling the biotech engine-2012 to 2013.

Authors:  Rob Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

8.  Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.

Authors:  Wei Huang; John Giddens; Shu-Quan Fan; Christian Toonstra; Lai-Xi Wang
Journal:  J Am Chem Soc       Date:  2012-07-16       Impact factor: 15.419

Review 9.  Chemical and chemoenzymatic synthesis of glycoproteins for deciphering functions.

Authors:  Lai-Xi Wang; Mohammed N Amin
Journal:  Chem Biol       Date:  2014-01-16

10.  Complementary MS methods assist conformational characterization of antibodies with altered S-S bonding networks.

Authors:  Lisa M Jones; Hao Zhang; Weidong Cui; Sandeep Kumar; Justin B Sperry; James A Carroll; Michael L Gross
Journal:  J Am Soc Mass Spectrom       Date:  2013-03-13       Impact factor: 3.109
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.